

Date: 12th August, 2025

To,
Department of Corporate Services,
BSE Limited,
P. J. Towers, Dalal Street Fort,
Mumbai - 400 001.

BSE Scrip Code: 524604

Sub.: Outcome of Meeting of Board of Directors held today i.e. 12.08.2025

Respected Sir/Madam,

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") this is to inform you that the Board of Directors of the Company at its Meeting held today, i.e., on Friday, 12th day of August, 2025 (which commenced at 04:40 p.m. and concluded at 05:15 p.m. inter alia, has approved/noted the following: -

1. Approval of the Unaudited Standalone Financial Results for the Quarter ended June 30, 2025:

Upon recommendation of the Audit Committee, the Board of Directors has approved the Unaudited Standalone Financial Result as per Indian Accounting Standards (IND AS) for the Quarter ended June 30, 2025 (enclosed herewith).

2. Noting of the Limited Review Report of the Statutory Auditors on the Unaudited Standalone Financial Results for the Quarter ended June 30, 2025:

The Limited Review Report of the Statutory Auditors for the Quarter ended June 30, 2025. The Board of Directors took note of the same (enclosed herewith).

3. Noting of SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2025/97 dated July 2, 2025:

The SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2025/97 dated July 2, 2025 issued under the *Ease of Doing Investments* initiative, providing a Special Window for Re-lodgement of Transfer Requests of Physical Shares was placed before the Board of Directors. The Board took the note of the same and instructed to take necessary steps with regard to the same.

We request you to please take the above information on your records.

Thanking you,

Yours sincerely,

For, Adline Chem Lab Limited



Sarang Bharatbhai Pathak
Managing Director
DIN: 02663344



CIN: L35106GJ1988PLC010956


ADLINE CHEM LAB LIMITED. (Formerly Kamron Laboratories Limited)

The Board of Directors**ADLINE CHEMLAB LIMITED****Independent Limited Review Report on the quarterly unaudited Standalone Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

1. We have reviewed the accompanying statement of unaudited financial results of Adline Chem Lab Ltd. (the "Company") for the quarter ended June 30, 2025 which include financial results ended on that date together with the relevant notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Regulations, 2015"). The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. This Statement, which is the responsibility of the Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with applicable Indian Accounting Standard ('Ind AS') and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Jain Kedia & Sharma
Chartered Accountants
FRN: 103920W**



Tarak
**Tarak Shah
Partner**

**Place: Ahmedabad
Date: August 12, 2025**

**Membership No. 182100
UDIN: 25182100BMODA05002**

ADLINE CHEMLAB LIMITED
 Regd. Office: A-514, Stellar, Opp. Arista Building, Sindhu Bhavan Road, Bodakdev, Ahmedabad - 380054,
 Gujarat, India
 CIN : L35106GJ1988PLC010956
STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2025

Particulars	(Rs. in Lakhs)			
	Quarter Ended		Year Ended	
	30th June 2025	31st Mar 2025	30th June 2024	31st Mar 2025
	Unaudited	Unaudited	Restated	Audited
Revenue from operations	-	-	-	-
Other income	-	24.89	-	24.89
Total Income	-	24.89	-	24.89
Expenses				
Cost of materials consumed	-	-	-	-
Purchase of Stock in Trade	-	-	-	-
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	-	-	-	-
Employee benefits expense	0.81	4.60	3.61	17.64
Finance costs	2.77	2.94	3.31	13.12
Depreciation and amortization expense	-	-	-	-
Other expenses	2.29	1.18	6.55	14.70
Total expenses	5.87	8.72	13.47	45.46
Profit/(loss) before exceptional items and tax	(5.87)	16.17	(13.47)	(20.57)
Exceptional Items	-	-	-	-
Profit/(loss) before tax	(5.87)	16.17	(13.47)	(20.57)
Tax expense:				
Current tax	(0.74)	(4.77)	(0.84)	(7.35)
Deferred tax	-	5.36	-	-
Prior period tax	(0.74)	-10.13	(0.84)	2.78
	-	-	-	-10.13
Profit (Loss) for the period from continuing operations	(5.13)	20.94	(12.63)	(13.22)
Profit/(loss) from discontinued operations	-	-	-	-
Tax expense of discontinued operations	-	-	-	-
Profit/(loss) from Discontinued operations (after tax)	-	-	-	-
Profit/(loss) for the period	(5.13)	20.94	(12.63)	(13.22)
Other Comprehensive Income				
Items that will not be reclassified to profit or loss (Net off tax)	0.15	(0.28)	0.46	1.10
Benefit due to actuarial valuation of gratuity	0.20	-0.37	0.61	1.46
Deferred tax	(0.05)	0.09	(0.15)	(0.37)
Items that will be reclassified to profit or loss (Net of tax)	-	-	-	-
Total Comprehensive Income for the period	(4.98)	20.66	(12.17)	(12.13)
Paid-up equity share capital (Face Value of the Share Rs. 10/- each)	585.00	585.00	585.00	585.00
Earnings per equity share [Not Annualised]:				
Basic	(0.01)	0.04	(0.02)	(0.02)
Diluted	(0.01)	0.04	(0.02)	(0.02)

Notes:

1. This statement has been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 Accounting Standards Rules, 2015 (as amended). The statutory auditors of the company have carried out limited review of the financial results for the quarter ended June 30, 2025.
2. These results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on August 12, 2025, and approved by the Board of Directors at its meeting held on August 12, 2025. The Statutory Auditors Report does not have any qualification or modification.
3. Since Ind AS 108, 'Operating Segment' is not applicable to the company, the company has not disclosed any segment information.
4. The figures for the quarter ended on March 31, 2025 are the balancing figures between audited figures for the full financial year and the published year-to-date figures up to the third quarter.

Place: Ahmedabad
 Date: August 12, 2025

For, Adline Chem Lab Limited



Sarang Pathak
 Managing Director
 DIN : 02663344

